Epithalon

Epitalon, also known as Epithalon or AEDG peptide (Ala-Glu-Asp-Gly), represents a synthetic tetrapeptide classified as an cellular senescence research compound. Originally derived from epithalamin, this peptide has garnered significant attention in gerontology research for its potential mechanisms affecting cellular cellular senescence. The primary mechanism of action centres on telomerase activation, an enzyme responsible for adding protective telomeric sequences to chromosome ends. Research indicates that Epitalon may stimulate this process, potentially influencing cellular aging pathways. A notable 2025 study from Brunel University published in Biogerontology demonstrated dose-dependent telomere extension through hTERT upregulation in normal cellular models. Interestingly, the research revealed that in cancer cell lines, telomere extension occurred via the alternative lengthening of telomeres (ALT) pathway rather than telomerase activation, representing an important safety consideration for future investigations. Beyond telomerase modulation, studies suggest Epitalon may influence the pineal gland's regulation of pineal hormone production, potentially affecting circadian rhythm maintenance. Research models have also indicated possible effects on immune function through thymus gland modulation, alongside potential reductions in oxidative stress markers. Primary research effects observed in laboratory studies include potential increases in telomere length, improvements in sleep quality parameters, immune function modulation, possible oxidative stress reduction, and circadian rhythm regulation. However, the evidence grade remains at level C, reflecting the need for more comprehensive clinical investigations. Notably, Western clinical trials remain absent from the current literature, emphasising the compound's status as a research-only tool for investigating aging mechanisms and cellular cellular senescence pathways in controlled laboratory environments.